{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:09Z","timestamp":1785465129055,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Peritoneal malignancies include primary and metastatic cancer of the peritoneal cavity. The most common origin for peritoneal metastasis is ovarian, gastric, and colorectal cancers. Irrespective of the origin, peritoneal metastases represent the advanced disease and are associated with poor long-term outcomes. The minimally invasive approach of pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows repeated applications and objective assessment of tumor response by comparing histological samples. This study aimed to investigate the initial experience with PIPAC in the Baltic region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients who underwent PIPAC at Vilnius University Hospital Santaros Klinikos between 2015 and 2020 were included in this retrospective study. The primary outcome of the study was overall survival (OS) in patients with peritoneal carcinomatosis treated by PIPAC. The secondary outcomes included postoperative morbidity; peritoneal carcinomatosis index (PCI) and ascites reduction after treatment by PIPAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 15 patients underwent 34 PIPAC procedures. PIPAC-related intraoperative and postoperative morbidity occurred in 3 (8.8%) of 34 procedures. Following PIPAC, the median PCI decreased from 8 (4; 15) to 5 (1; 16) in GC patients, although, the difference failed for significance, <jats:italic>p<\/jats:italic> = 0.581. In OC patients, PCI after PIPAC remained stable. Median overall survival after PIPAC procedure was 25 (95% CI 5\u201344) months. Ovarian cancer patients (22; 95% CI 12\u201344 months) had significantly higher OS, compared to gastric cancer patients (8; 95% CI 4\u201316 months), <jats:italic>p<\/jats:italic> = 0.018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PIPAC is safe and feasible for patients with gastric and ovarian cancers peritoneal metastases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02357-5","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:02:27Z","timestamp":1628618547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6116-2930","authenticated-orcid":false,"given":"Rokas","family":"Ra\u010dkauskas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustinas","family":"Bau\u0161ys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martynas","family":"Luk\u0161ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Jurgaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Pa\u0161konis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u0119stutis","family":"Strupas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"7","key":"2357_CR1","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(19)30318-3.","journal-title":"Lancet Oncol."},{"issue":"2","key":"2357_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","volume":"21","author":"W Solass","year":"2014","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"2357_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000493493","volume":"34","author":"PK Garg","year":"2018","unstructured":"Garg PK, Brandl A, Rau B. Hyperthermic intraperitoneal chemotherapy - fading perspective in the light of modern systemic chemotherapy? Visc Med. 2018;34(6):412\u20136. https:\/\/doi.org\/10.1159\/000493493.","journal-title":"Visc Med"},{"issue":"11","key":"2357_CR4","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1245\/s10434-013-3039-x","volume":"20","author":"W Solass","year":"2013","unstructured":"Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504\u201311. https:\/\/doi.org\/10.1245\/s10434-013-3039-x.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"2357_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"10","key":"2357_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4(10):761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"23","key":"2357_CR7","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"P-E Bonnot","year":"2019","unstructured":"Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(23):2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"9","key":"2357_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(20)30338-7","volume":"21","author":"BJ Moran","year":"2020","unstructured":"Moran BJ. PROPHYLOCHIP: no benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2020;21(9):1124\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(20)30338-7.","journal-title":"Lancet Oncol."},{"key":"2357_CR9","doi-asserted-by":"publisher","first-page":"175883591877703","DOI":"10.1177\/1758835918777036","volume":"10","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036.","journal-title":"Ther Adv Med Oncol."},{"issue":"1","key":"2357_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cancers12010034","volume":"12","author":"G Nadiradze","year":"2019","unstructured":"Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich F-J, K\u00f6nigsrainer A, et al. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancers. 2019;12(1):34 [cited 2021 Feb 15];12. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7016575\/.","journal-title":"Cancers"},{"issue":"6","key":"2357_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/bjs.10521","volume":"104","author":"F Grass","year":"2017","unstructured":"Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, H\u00fcbner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. BJS Br J Surg. 2017;104(6):669\u201378. https:\/\/doi.org\/10.1002\/bjs.10521.","journal-title":"BJS Br J Surg."},{"issue":"7","key":"2357_CR12","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311\u20136. https:\/\/doi.org\/10.1245\/s10434-012-2840-2.","journal-title":"Ann Surg Oncol."},{"key":"2357_CR13","doi-asserted-by":"crossref","unstructured":"Alyami M, Bonnot P-E, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2020;47(1):123-7.","DOI":"10.1016\/j.ejso.2020.05.021"},{"key":"2357_CR14","first-page":"20180108","volume":"3","author":"M Graversen","year":"2018","unstructured":"Graversen M, Detlefsen S, Asmussen J, Mahdi B, Fristrup C, Pfeiffer P, et al. Treatment of peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy \u2013 PIPAC-OPC2. Pleura Peritoneum. 2018;3:20180108.","journal-title":"Pleura Peritoneum."},{"issue":"21","key":"2357_CR15","first-page":"00492","volume":"S0748-7983","author":"S Granieri","year":"2021","unstructured":"Granieri S, Bonomi A, Frassini S, Chierici AP, Bruno F, Paleino S, et al. Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: a meta-analysis of randomized controlled trials. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021;S0748-7983(21):00492\u20133.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"1","key":"2357_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0300891619868013","volume":"106","author":"I Gockel","year":"2020","unstructured":"Gockel I, Jansen-Winkeln B, Haase L, Niebisch S, Moulla Y, Lyros O, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer. Tumori. 2020;106(1):70\u20138. https:\/\/doi.org\/10.1177\/0300891619868013.","journal-title":"Tumori."},{"issue":"2","key":"2357_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2013.11.022","volume":"132","author":"CB Tempfer","year":"2014","unstructured":"Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, et al. Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132(2):307\u201311. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.022.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"2357_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12885-020-6572-6","volume":"20","author":"M Ploug","year":"2020","unstructured":"Ploug M, Graversen M, Pfeiffer P, Mortensen MB. Bidirectional treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020;20(1):105. https:\/\/doi.org\/10.1186\/s12885-020-6572-6.","journal-title":"BMC Cancer."},{"issue":"1","key":"2357_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","volume":"14","author":"R Girshally","year":"2016","unstructured":"Girshally R, Demtr\u00f6der C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14(1):253. https:\/\/doi.org\/10.1186\/s12957-016-1008-0.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"2357_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejso.2019.03.021","volume":"47","author":"M Siebert","year":"2021","unstructured":"Siebert M, Alyami M, Mercier F, Gallice C, Villeneuve L, Laplace N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study. Eur J Surg Oncol. 2021;47(1):139\u201342. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.021.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"2357_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14(1):128. https:\/\/doi.org\/10.1186\/s12957-016-0892-7.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"2357_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12957-019-1633-5","volume":"17","author":"J Schubert","year":"2019","unstructured":"Schubert J, Khosrawipour V, Chaudhry H, Arafkas M, Knoefel WT, Pigazzi A, et al. Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC). World J Surg Oncol. 2019;17(1):93. https:\/\/doi.org\/10.1186\/s12957-019-1633-5.","journal-title":"World J Surg Oncol."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02357-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:02:39Z","timestamp":1628618559000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02357-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02357-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vilnius Regional Biomedical Research Ethics Committee approval (No. 2020\/11-1279-761) was obtained before this study was conducted. The study was conducted according to the Declaration of Helsinki. Informed consent was waived by the Vilnius Regional Biomedical Research Ethics Committee that approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}